Q-Linea
Q-linea presents at Stockholm Corporate Finance 15th Life Science Capital Market Days (MFN)
Q-linea is participating in the Stockholm Corporate Finance 15th Life Science Capital Markets Days on March 8 - 9, 2023 at the IVA conference center in Stockholm. Q-linea’s CEO Jonas Jarvius presents on March 8 at 9:00 – 9:30 the latest developments and the future of the company.
Stockholm Corporate Finance organizes the capital market days for the fifteenth year in a row in collaboration with Financial Hearings and Infront Direkt Studios, which is an independent part of Nyhetsbyrån Direkt. If you want to register as a participant for the capital markets day, use this link, Stockholm Corporate Finance 15e Life Science Seminarium den 8-9 mars 2023 (lyyti.fi)
For more information, please contact:
Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60
Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.